Highlights from ACR Convergence 2024: Groundbreaking LRA-Funded Research and Innovative Therapies
December 5, 2024 —
The Lupus Research Alliance (LRA) is proud to showcase the groundbreaking work of its funded researchers...
Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network
Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network
NEW YORK, NY, October 24, 2023 — The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, announced a partnership with AbbVie Inc. for the Phase 3 development of upadacitinib (RINVOQ®) as a potential treatment for people living with systemic lupus erythematosus (SLE). Lupus Therapeutics will assist with recruiting participants to join the study, activation of each study site and engaging sites to join the study through the Lupus Clinical Investigators Network (LuCIN) of top academic centers throughout North America.
The full press release is available on the Lupus Therapeutics website.
